Related Experiment Video
Updated: Mar 17, 2026
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Friend or foe? Targeting microglia in Alzheimer's disease
1Department of Neurology, 125 Paterson Street, Suite 6200, New Brunswick, NJ 08901, United States.
Abstract:
Inflammation is believed to be a component of a number of degenerative brain diseases including Alzheimer's disease. A recent article by Fu and colleagues (2016) demonstrated that the cytokine IL-33 can modulate microglia in an animal model of AD to become better scavengers of beta-amyloid and less pro-inflammatory. The findings have potential therapeutic implications for a number of brain conditions.
Insights
The cytokine Interleukin-33 (IL-33) can reprogram microglia to clear beta-amyloid and reduce inflammation in an Alzheimer's disease animal model. This finding suggests IL-33 as a potential therapeutic target for neurodegenerative diseases.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Neuroinflammation is a key factor in Alzheimer's disease (AD) pathogenesis.
- Microglia, the brain's immune cells, play a dual role in AD, potentially exacerbating or resolving pathology.
- The cytokine Interleukin-33 (IL-33) is implicated in immune regulation.
Purpose of the Study:
- To investigate the role of IL-33 in modulating microglial function in an AD context.
- To determine if IL-33 can alter microglial phagocytosis of beta-amyloid and their inflammatory state.
Main Methods:
- Utilized an animal model of Alzheimer's disease.
- Administered or modulated IL-33 levels.
- Assessed microglial activation state and phagocytic capacity for beta-amyloid.
Main Results:
- IL-33 treatment shifted microglia towards a less pro-inflammatory phenotype.
- IL-33 enhanced microglial scavenging of beta-amyloid plaques.
- Modulation of microglia by IL-33 was demonstrated in vivo.
Conclusions:
- The cytokine IL-33 can reprogram microglia to adopt a neuroprotective phenotype in AD.
- Targeting IL-33 may offer a novel therapeutic strategy for Alzheimer's disease.
- These findings highlight the potential of immunomodulatory approaches for neurodegenerative disorders.
